Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection

Тенектеплаза при инсульте через 4,5–24 часа с отбором пациентов по данным перфузионной визуализации
David S. Liebeskind, Gregory W. Albers, Bruce C.V. Campbell, Maarten G. Lansberg, Ashfaq M Shuaib, Lee H. Schwamm, Mouhammad Jumaa, Barbara Purdon, Syed Zaidi, Christopher D. Streib, Navdeep S Sangha, Minjee Kim, Michael T. Froehler, Neil E Schwartz, Wayne M. Clark, Charles E. Kircher, Ming Yang, Lori Massaro, Xiao-Yu Lü, Gregory A. Rippon, Joseph P. Broderick, Kenneth Butcher, Amre M Nouh, Charles E Kircher
2024-02-08

late-window ischemic strokemiddle cerebral artery occlusionmodified Rankin Scaleperfusion imagingtenecteplase
BACKGROUND: Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after the onset of stroke symptoms. Information on whether tenecteplase confers benefit beyond 4.5 hours is limited. METHODS: We conducted a multicenter, double-blind, randomized, placebo-controlled trial involving patients with ischemic stroke to compare tenecteplase (0.25 mg per kilogram of body weight, up to 25 mg) with placebo administered 4.5 to 24 hours after the time that the patient was last known to be well. Patients had to have evidence of occlusion of the middle cerebral artery or internal carotid artery and salvageable tissue as determined on perfusion imaging. The primary outcome was the ordinal score on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability and a score of 6 indicating death) at day 90. Safety outcomes included death and symptomatic intracranial hemorrhage. RESULTS: The trial enrolled 458 patients, 77.3% of whom subsequently underwent thrombectomy; 228 patients were assigned to receive tenecteplase, and 230 to receive placebo. The median time between the time the patient was last known to be well and randomization was approximately 12 hours in the tenecteplase group and approximately 13 hours in the placebo group. The median score on the modified Rankin scale at 90 days was 3 in each group. The adjusted common odds ratio for the distribution of scores on the modified Rankin scale at 90 days for tenecteplase as compared with placebo was 1.13 (95% confidence interval, 0.82 to 1.57; P = 0.45). In the safety population, mortality at 90 days was 19.7% in the tenecteplase group and 18.2% in the placebo group, and the incidence of symptomatic intracranial hemorrhage was 3.2% and 2.3%, respectively. CONCLUSIONS: Tenecteplase therapy that was initiated 4.5 to 24 hours after stroke onset in patients with occlusions of the middle cerebral artery or internal carotid artery, most of whom had undergone endovascular thrombectomy, did not result in better clinical outcomes than those with placebo. The incidence of symptomatic intracerebral hemorrhage was similar in the two groups. (Funded by Genentech; TIMELESS ClinicalTrials.gov number, NCT03785678.).
1
A multicenter, double-blind randomized trial evaluated tenecteplase 4.5–24 hours after stroke onset in patients with large-artery occlusion and salvageable tissue on perfusion imaging.
2
Among 458 patients, 77.3% underwent thrombectomy; tenecteplase was administered to 228 patients and placebo to 230.
3
Median 90-day modified Rankin Scale scores were 3 in both treatment groups.
4
Mortality and symptomatic intracranial hemorrhage were numerically higher with tenecteplase than placebo: 19.7% versus 18.2% and 3.2% versus 2.3%, respectively.
5
Tenecteplase did not significantly improve 90-day functional outcomes compared with placebo, with an adjusted common odds ratio of 1.13 (95% CI, 0.82–1.57; P=0.45).

Patients with ischemic stroke caused by middle cerebral artery or internal carotid artery occlusion and salvageable tissue 4.5 to 24 hours after they were last known to be well

The efficacy and safety of delayed tenecteplase therapy, assessed by 90-day functional outcome, mortality, and symptomatic intracranial hemorrhage

Publication Details
Publication Date
2024-02-08
Journal
Publisher
ISSN
Cited by
237
Access Type
Author Information
Authors
David S. Liebeskind
Gregory W. Albers
Bruce C.V. Campbell
Maarten G. Lansberg
Ashfaq M Shuaib
Lee H. Schwamm
Mouhammad Jumaa
Barbara Purdon
Syed Zaidi
Christopher D. Streib
Navdeep S Sangha
Minjee Kim
Michael T. Froehler
Neil E Schwartz
Wayne M. Clark
Charles E. Kircher
Ming Yang
Lori Massaro
Xiao-Yu Lü
Gregory A. Rippon
Joseph P. Broderick
Kenneth Butcher
Amre M Nouh
Charles E Kircher
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%